BR0008443A - Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética - Google Patents

Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética

Info

Publication number
BR0008443A
BR0008443A BR0008443-3A BR0008443A BR0008443A BR 0008443 A BR0008443 A BR 0008443A BR 0008443 A BR0008443 A BR 0008443A BR 0008443 A BR0008443 A BR 0008443A
Authority
BR
Brazil
Prior art keywords
amino acid
diabetic retinopathy
dependent
branched
treatment
Prior art date
Application number
BR0008443-3A
Other languages
English (en)
Inventor
Justin Stephen Bryans
Lain-Yen Hu
Susan M Hutson
Kathrynfoley Lanoue
Erich Lieth
Michael Francis Rafferty
Todd Robertryder
Ti-Zhi Su
Devin Franklin Welty
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Penn State Res Found
Univ Wake Forest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Penn State Res Found, Univ Wake Forest filed Critical Warner Lambert Co
Publication of BR0008443A publication Critical patent/BR0008443A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: "INIBIDORES DE AMINOTRANSFERASEAMINOáCIDO-DEPENDENTE DE CADEIA RAMIFICADA E SEUUSO NO TRATAMENTO DA RETINOPATIA DIABéTICA". Apresente invenção refere-se a um método para o tratamentoprofilático e terapêutico da retinopatia diabética. O método envolvea administração de um inibidor do caminho da aminotransferaseaminoácido-dependente de cadeia ramificada (BCAT) a um animal,tal como um mamífero, em particular um ser humano, em umaquantidade suficiente para tratar a retina para retinopatia diabéticaprofilaticamente ou terapeuticamente. A presente invençãotambém refere-se a vários novos inibidores do caminho da BCAT.
BR0008443-3A 1999-12-08 2000-11-08 Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética BR0008443A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16963599P 1999-12-08 1999-12-08
US17539900P 2000-01-11 2000-01-11
US23002000P 2000-09-05 2000-09-05
PCT/US2000/030769 WO2001042191A1 (en) 1999-12-08 2000-11-08 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy

Publications (1)

Publication Number Publication Date
BR0008443A true BR0008443A (pt) 2001-10-30

Family

ID=27389690

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008443-3A BR0008443A (pt) 1999-12-08 2000-11-08 Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética

Country Status (33)

Country Link
EP (1) EP1157000B1 (pt)
JP (1) JP2003516379A (pt)
KR (1) KR20010101811A (pt)
CN (2) CN1170811C (pt)
AP (1) AP2001002242A0 (pt)
AR (1) AR037738A1 (pt)
AT (1) ATE308510T1 (pt)
AU (1) AU784553B2 (pt)
BG (1) BG105875A (pt)
BR (1) BR0008443A (pt)
CA (1) CA2361647A1 (pt)
CO (1) CO5280055A1 (pt)
CZ (1) CZ20012758A3 (pt)
DE (1) DE60023657T2 (pt)
DZ (1) DZ3141A1 (pt)
EA (1) EA006597B1 (pt)
EE (1) EE200100416A (pt)
ES (1) ES2252075T3 (pt)
GE (1) GEP20043298B (pt)
HK (1) HK1044933B (pt)
HR (1) HRP20010581A2 (pt)
HU (1) HUP0200570A3 (pt)
IS (1) IS6033A (pt)
MA (1) MA26777A1 (pt)
MX (1) MXPA01008085A (pt)
NO (1) NO20013844L (pt)
OA (1) OA11759A (pt)
PE (1) PE20010929A1 (pt)
PL (1) PL349193A1 (pt)
SK (1) SK11022001A3 (pt)
UY (1) UY26474A1 (pt)
WO (1) WO2001042191A1 (pt)
YU (1) YU57401A (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345664C1 (en) * 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MXPA02010430A (es) * 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
ES2295751T3 (es) * 2004-09-20 2008-04-16 Kao Corporation Procedimiento para preparar lactonas y uso de las mismas como material odorifero.
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2008103319A2 (en) * 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008155619A2 (en) * 2007-06-21 2008-12-24 Pfizer Inc. Preparation of optically-active cyclic amino acids
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2481801A1 (en) 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
US9422224B2 (en) * 2011-06-13 2016-08-23 Ergon Pharmaceuticals Llc Methods of treatment using a BCAT1 inhibitor
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
CN111635937B (zh) * 2020-06-29 2021-10-08 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708200A (pt) * 1996-03-14 1999-07-27 Warner Lambert Co Aminoácidos cíclicos substituídos como agentes farmacéuticos

Also Published As

Publication number Publication date
KR20010101811A (ko) 2001-11-14
EA006597B1 (ru) 2006-02-24
NO20013844D0 (no) 2001-08-07
PE20010929A1 (es) 2001-09-08
EP1157000A1 (en) 2001-11-28
HK1044933A1 (en) 2002-11-08
YU57401A (sh) 2004-05-12
EE200100416A (et) 2002-12-16
PL349193A1 (en) 2002-07-01
HUP0200570A3 (en) 2003-02-28
CA2361647A1 (en) 2001-06-14
DZ3141A1 (fr) 2001-01-14
CN1626069A (zh) 2005-06-15
EA200100791A1 (ru) 2002-04-25
DE60023657D1 (de) 2005-12-08
NO20013844L (no) 2001-10-04
DE60023657T2 (de) 2006-07-20
MXPA01008085A (es) 2002-04-24
SK11022001A3 (sk) 2002-11-06
AP2001002242A0 (en) 2001-09-30
AU1477901A (en) 2001-06-18
GEP20043298B (en) 2004-03-10
IS6033A (is) 2001-07-31
UY26474A1 (es) 2001-01-31
OA11759A (en) 2005-07-19
BG105875A (en) 2002-05-31
JP2003516379A (ja) 2003-05-13
AR037738A1 (es) 2004-12-01
CO5280055A1 (es) 2003-05-30
CZ20012758A3 (cs) 2002-09-11
HRP20010581A2 (en) 2002-08-31
MA26777A1 (fr) 2004-12-20
ES2252075T3 (es) 2006-05-16
EP1157000B1 (en) 2005-11-02
CN1344245A (zh) 2002-04-10
ATE308510T1 (de) 2005-11-15
CN1170811C (zh) 2004-10-13
HK1044933B (zh) 2005-06-03
HUP0200570A2 (en) 2002-06-29
WO2001042191A1 (en) 2001-06-14
AU784553B2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BR0008443A (pt) Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
ATE202923T1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
WO2001041707A3 (en) Modulation of in vivo glutamine and glycine levels in the treatment of autism
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
NO20023464D0 (no) Sammensetning for intestinal avlevering
PL1677806T3 (pl) Sposoby leczenia ostrego i nadmiernego skręcenia i naciągnięcia przy użyciu kwasu hialuronowego
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
IS7912A (is) Notkun dókósahexensýru sem virks efnis til að meðhöndla fitukyrking
BR0115215A (pt) Método para o tratamento de inflamações
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
ECSP003814A (es) Inhibidores de aminotransferasa dependiente de aminoacidos de cadena ramificada y su uso en el tratamiento de la retinopatia diabetica.
BR0212991A (pt) Métodos de tratamento oftalmológico utilizando inibidores seletivos de inos
Floor et al. XIAFLEX should be administered by a health professional:• Experienced in injection procedures of the hand and in the treatment of patients with Dupuytren’s contracture, or• Appropriately trained in the correct administration of the medicinal product and experienced in the diagnosis and treatment of male urological diseases.
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
TNSN03022A1 (en) Method for treatment of inflammation
UA41815A (uk) Спосіб лікування пародонтиту

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.